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ABSTRACT 
Sepsis is a growing global healthcare concern and is related to high morbidity and mortality. 
Studies have repeatedly demonstrated that the rapid administration of appropriate 
antimicrobial treatment is crucial for patient survival. Thus, receiving timely and actionable 
information from the laboratory on identification of the microorganism causing sepsis is 
crucial for patient management.   
In today’s routine diagnostics, blood culture is the standard method for diagnosing sepsis and 
identification of microorganisms is based on sub-culturing the positive blood culture bottles.   
The overall aim of this thesis was to evaluate and improve the use of rapid identification 
methods in identification of microorganisms directly from blood culture bottles. 
The thesis focused on two methods, FilmArray and MALDI-TOF MS. The present studies 
showed that the identification of microorganisms from a blood culture bottle by FilmArray 
and MALDI-TOF MS were ready in 65 min and 30 minutes respectively.  
The most common form of sepsis is caused by a single microorganism. In paper 1 we studied 
the performance of FilmArray in identification of microorganism’s form blood culture 
bottles. The FilmArray could identify the microorganism in 91.6% of the blood culture 
bottles. 
The anaerobic bacteria are not covered by current rapid identification methods including 
FilmArray. In study 3, we analyzed the performance of MALDI-TOF MS in identification of 
anaerobic bacteria from four different blood culture bottle types. MALDI-TOF MS could 
identify anaerobic bacteria in between 75-79% of the different blood culture bottle types. 
The incidence of detection of polymicrobial growth in blood culture bottles is increasing. 
This is an obvious challenge both for conventional and rapid identification methods. In study 
1 and 4 we evaluated the performance of rapid methods in identification of polymicrobial 
growth directly from blood culture (BC) bottles after positivity.  FilmArray correctly 
identified all microorganisms in 17/24 (71%) and 99/115 (86.1%) of the BC bottles in study 1 
and 4 respectively. In contrast, the present MALDI-TOF MS method showed poor 
performance and could identify both microorganisms in only 2/115 (1.7%) blood culture 
bottles. 
The high analytical performance of the current rapid methods stimulated us to ask the 
question if we can identify microorganisms from bottles before the blood cultures signals 
positive. We called this unique approach as semi-culture based identification since the full-
term culture is not needed.  
In study 2, we analyzed the semi-culture based identification by FilmArray and MALDI-TOF 
MS. We analyzed both simulated and clinical blood cultures with this approach. MALDI-
TOF MS failed to identify the microorganisms prior to positivity even in the simulated blood 
culture bottles. Interestingly, FilmArray could identify microorganisms from bottles before 
  
 
the blood cultures signals positive both in simulated and clinical blood culture bottles. In 
simulated samples, the median time to detection (TTD) of growth for the bottles in the blood 
culture system was 11.1 h, whereas FilmArray could identify microorganisms after 5 h 
incubation in the system.  
In conclusion, the present thesis shows that the FilmArray is a reliable method for 
identification of microorganisms from positive blood culture bottles with mono- as well as 
polymicrobial growth. The data from the studies showed also that it is possible to improve the 
use of rapid identification methods as in the case of semi-culture based identification.  
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1 INTRODUCTION 
Sepsis is a major health concern worldwide since it is related to high morbidity, mortality and 
huge health care related costs (Goto and Al-Hasan, 2013, Angus et al., 2001). The true 
incidence of the disease is unknown. However there is accumulating evidence that sepsis is 
an increasingly common problem affecting both developed and developing countries 
(Kissoon et al., 2011).  
1.1 DEFINITION OF SEPSIS 
The devastating nature of sepsis has not only stimulated modern clinical researcher but also 
the scientific community in ancient times.  
The complex nature of sepsis has brought complex and interesting questions that needed to be 
answered by the scientific community. It is possible to state that one of the major problems 
with sepsis has been to define what sepsis is.  
The definition of the disease is obviously decisive in order to describe the etiology, 
epidemiology, pathophysiology of the disease and to develop effective diagnostic approaches. 
In addition, the clinical studies aiming to develop and study new treatment approaches is 
completely dependent on the definition of the disease.   
The term “sepsis” was first used by Hippocrates (ca. 460-370 BC). It is originated from the 
word “sipsi” meaning “make rotten” in Greek. Later, Ibn Sina (979-1037 BC) described the 
coincidence of fever and blood putrefaction (sepsis).  
In 1850s, Semmelweiss (Noakes et al., 2008) described the cause of childbed fever as 
"decomposed animal matter that entered the blood system". Subsequently, Pasteur and others 
proposed the theory of sepsis or “blood poisoning” as disseminated infection caused by an 
invasion of a pathogen (Altemeier, 1982). 
The first consensus conference in establishing a set of definitions for sepsis and its sequel was 
made in 1991 (Sepsis-1). The international recommendations for definition of systemic 
inflammatory response syndrome (SIRS), sepsis, severe sepsis and septic shock were 
established and published in 1992 (Bone et al., 1992).  
Improved understanding of the pathophysiology of sepsis during time resulted in the second 
consensus conference. The definition from the first conference was modified (Singer et al., 
2016). The consensus conference defined sepsis to be the clinical syndrome defined by the 
presence of both infection and a systemic inflammatory response (Sepsis-2) (Fig. 1). 
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Fig. 1 Definitions of SIRS, Sepsis, Severe Sepsis and Septic Shock. 
However, several studies have shown that the use of SIRS criteria as a parameter for sepsis 
diagnosis resulted in incorrect diagnosis as sepsis even in the absence of infection (Singer et 
al., 2016). The need for a more specific definition resulted in the third international 
definitions for sepsis and septic shock (Sepsis-3).  
According to the new classification, sepsis is now defined as an evidence of infection with 
life-threatening organ dysfunction, clinically characterized by 2 points or greater in organ 
failure assessment score (SOFA) (Singer et al., 2016).  
The new criteria for septic shock include fluid-unresponsive hypotension, serum lactate levels 
more than 2 mmol/L, and the requirement for vasopressors to maintain the arterial pressure of 
65 mmHg or more. 
Another definition that is probably most related to microbiological diagnosis of sepsis is 
blood stream infection. This definition is based on detection of microorganisms in the blood 
stream. For newborns and infants however, the term clinical sepsis is used (Horan et al., 
2008). 
The present doctoral thesis is focused on microbiological diagnosis of sepsis. Therefore the 
present work is inevitable challenged by continuously changing definitions of the disease. 
During the study period the patients were diagnosed in the clinical routine according to 
Sepsis-2 criteria.  
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However, the project focused on positive blood cultures. Therefore, in our scientific article 
we preferred to use the term bloodstream infections because it represents the 
microbiologically diagnosed patients with sepsis.  
However, in writing the thesis the term sepsis is preferred. The underlying reason for this 
discrepancy and using the term sepsis is to describe the published material on etiology, 
epidemiology of the disease. The majority of these articles preferred to use the term sepsis.  
1.2 INCIDENCE OF SEPSIS 
As described above the problems in definition of sepsis have resulted in difficulties in 
measuring the incidence and prevalence of the disease. However, it is important to describe 
the current data on the incidence of sepsis in different settings and geographical locations 
regardless of the limitations. 
Several studies have shown that sepsis incidence is increasing with the population growth 
in USA (Martin et al., 2003, Dombrovskiy et al., 2005, Dombrovskiy et al., 2007, Martin, 
2012). Other studies existing from Australia, UK, Croatia and Saudi Arabia showing 
similar figures (Finfer et al., 2004, Harrison et al., 2006, Degoricija et al., 2006, Baharoon 
et al., 2015, Sudhir et al., 2011, Sundararajan et al., 2005). 
At high income countries sever sepsis incidence is reported to be between 50 and 100 cases 
per 100,000 (Danai and Martin, 2005). Sepsis incidence is shown to be three to four times 
higher than the percentage of organ dysfunction syndrome which is the most severe form of 
sepsis (Martin et al., 2003).  
At present more than 1,000,000 cases of sepsis of patients admitted to the hospital per year 
at USA (Martin, 2012).  
In the low-income countries incidences of sepsis are less well-described (Adhikari et al., 
2010). It has been reported that the incidence of sepsis increases in young individuals in 
low income counters (Berkley et al., 2005). 
In countries where data for sepsis are obtainable the number of sepsis cases has increased 
(Kaukonen et al., 2014, Shen et al., 2010, Hall et al., 2011).  
It was pointed that the number of hospital admissions for sepsis increased up to three-fold in 
comparison with myocardial infarction and stroke that remained the same over the past few 
decades (Seymour et al., 2012, Kempker and Martin, 2016) (Fig. 2). 
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Fig. 2 Hospital admissions of sepsis compared to stroke and myocardial infarction among 
emergency medical service (EMS). (Circles= severe sepsis; Triangles=AMI; Squares= 
stroke). This figure was adopted from (Seymour et al., 2012). 
Recent studies showed that ethnic background and gender may contribute to the risk for 
development of sepsis (Martin et al., 2003, Esper et al., 2006, Mayr et al., 2010). Males 
have higher risk than females in developing sepsis regardless of age (Martin et al., 2003, 
Dombrovskiy et al., 2007, Esper et al., 2006).  
The reasons behind the differences in the incidence of sepsis regarding the ethnicity and 
gender are not known (Esper et al., 2006, Dombrovskiy et al., 2007, Martin et al., 2003). 
1.3 PATIENT OUTCOME 
Sepsis remains one of the main causes of decreasing life expectancy (Semeraro et al., 2010). 
The mortality rates differ worldwide due to numerous factors such as age, comorbid disease, 
access to health care, regional health patterns as well as genomic influences (Martin, 2012).  
The patients with sepsis in ICUs have higher average of mortality rates (Vincent et al., 2006). 
Furthermore, costs to treat patients with sepsis are quite large with an estimate from cost from 
US$25,000 to $50,000 per episode worldwide (Edbrooke et al., 1999, Schmid et al., 2002, 
Brun-Buisson et al., 2003, Schmid et al., 2004, Moerer et al., 2007).  
From data shown back in 1979 the risk of dying was near 30% in the early years and the year 
2000 the risk has been under 20% (Martin, 2012). In USA, each year more than 200,000  
patients die because of sepsis (Martin, 2012). 
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1.4 ETIOLOGY OF BLOODSTREAM INFECTION (BSI, SEPSIS)  
It is possible to suggest that a wide range of microorganisms have the ability to cause sepsis. 
These include bacteria, fungi and protozoa. However the most common cause of sepsis is 
bacteria and yeast.  
There are several different types of underlying diseases and conditions which may induce the 
development of sepsis, including chronic illnesses, or the patients receiving chemotherapy or 
immunosuppressive drugs (Angus et al., 2001, Barchiesi et al., 2016).  
Among the underlying diseases in ICU patients, respiratory infections are the most common 
source for sepsis, followed by genitourinary and abdominal infections (Martin et al., 2003, 
Danai et al., 2007). 
Table 1 Underlying disease of sepsis. This table was adopted and modified from (Sudhir et 
al., 2011). 
Source of infection if sepsis 
1. Respiratory tract infection 
2. Urinary tract infection 
3. Gastrointestinal tract infection 
4. Malaria 
5. Cellulites   
6. Dengue 
7. Source not found  
The microorganism causing the initial infection naturally dominates as BSI pathogen.  
In general, the proportions of Gram-negative and Gram-positive bacteria causing sepsis are 
similar. The most common Gram-negative bacteria are Escherichia coli, Klebsiella species, 
Pseudomonas aeruginosa, Enterobacter species and Serratia species, while Staphylococcus 
aureus, CoNS, Enterococcus species, viridans streptococci and Streptococcus pneumoniae 
are reported to be the most common Gram-positive bacteria causing sepsis (Biedenbach et al., 
2004, Tosson and Speer, 2011).   
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Even anaerobic bacteria are important as causative microorganisms of sepsis. The 
predominant anaerobic bacterial species in sepsis is Bacteroides fragilis. In contrast, 
anaerobic cocci and Clostridium species are infrequently isolated from sepsis patients (Nord, 
1982). 
The incidence of sepsis due to yeast are increasing. Candidemia is currently regarded as the 
fourth most common BSI in ICUs. Candida albicans has been dominating as the major 
pathogen causing candidemia. The epidemiology of candidemia has however changed rapidly 
over time resulting in more frequent detection of other Candida species, including Candida 
glabrata and Candida krusei (Diekema et al., 2012, Pittet and Wenzel, 1995, Trick and 
Jarvis, 1998). 
The extended diversity among the microorganisms causing sepsis and the differences in 
antimicrobial susceptibility profiles result in difficulties in treating patients. Therefore the 
microbiological diagnosis of sepsis has the most importance for selection of effective and 
appropriate antimicrobial treatment of patients with sepsis. 
 
Fig. 3 Shows the microorganisms causing sepsis over time (Martin et al., 2003). 
1.5 TREATMENT OF SEPSIS 
Empiric antibiotic therapy is defined as broad spectrum treatment that covers the most 
common microorganisms causing sepsis in a patient and is chosen in relation to other clinical 
signs and the prevalence of antimicrobial resistance in a given geographical area.  
The International Committee on Surviving Sepsis (SSC) recommends that patients with 
suspected sepsis need to be treated with antibiotics within the first hour of diagnosis 
(Dellinger et al., 2004). It was shown that this early empiric antibiotic therapy reduces 
mortality rate (Dellinger et al., 2013, Levy et al., 2014, Ferrer et al., 2014). The majority of 
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these studies were observational and retrospective studies (Ibrahim et al., 2000, Zaragoza et 
al., 2003, Kollef et al., 1999, Vogelaers et al., 2010).  
On the other hand, empiric antibiotic treatment can have several negative effects, such as 
adverse effects related to the drug itself, alterations of the host microbiome, development of 
opportunistic infections and probably the increased risk for multidrug-resistant 
microorganisms (Havey et al., 2013).  
Most importantly, empiric antibiotic treatments cannot cover all microorganisms and can thus 
have only limited effect (Leekha et al., 2011).  
Therefore, the microbiological diagnosis is the only way for an effective, safe and economic 
treatment of patients with sepsis. The SSC recommends blood samples to be drawn before 
initiating antibiotic therapy so that the initial empirical therapy can be corrected for 
appropriate, targeted antibiotics when the culture result is available.  
1.6 LABORATORY DIAGNOSIS OF SEPSIS 
The significant changes in a broad range of parameters in patients with sepsis provide the 
possibility to diagnose sepsis by the help of laboratory analysis of blood. As described above 
the diagnosis of sepsis and SIRS depends mainly on laboratory results describing biochemical 
and hematologic parameters.  
These results are generally available within a short period of time, not exceeding an hour. The 
information obtained by these rapid laboratory investigations is invaluable help to start 
supportive therapy in order to save the lives of patients.  
Unfortunately, the information is mainly unspecific and does not reveal the identity of the 
causing microorganism. Microbiological diagnostic remains therefore crucial for selection of 
specific antimicrobial therapy. 
1.7 MICROBIOLOGICAL DIAGNOSIS OF SEPSIS 
The microbiological diagnosis of sepsis is a complex process. Today there are two 
approaches to detect and identify microorganisms from patients with sepsis, culture-
independent methods, and culture-dependent methods. 
The culture-independent methods have been developing during the recent years and have so 
far very limited availability in the clinical routine. In contrast, blood cultures have been used 
in the clinical routine for more than 100 years and are still regarded the gold standard in 
microbiological diagnostics of sepsis.  
Unfortunately, blood culture-based diagnosis is not optimal as the turn-around time for the 
microbiology results is relatively long.  
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There are several different aspects of blood culture-based diagnostics, which need to be 
considered in the development of new methods providing reliable microbiological results 
within short turn-around time (Banerjee et al., 2016).  
They can be assigned to three major parts in this process, namely pre-analytical, analytical 
and post-analytical procedures. These parts in turn include several different moments as 
described in Table 2.   
The pre-analytical part covers the procedures prior to detection of growth in the blood 
culture. When the clinical diagnosis of sepsis is made, the first step is to collect blood cultures 
for microbiological diagnosis of sepsis.  
Then the bottles need to be transported to the laboratory. After arrival in the laboratory the 
bottles should be registered in the laboratory information system and placed onto blood 
culture instruments.  
The analytical part starts with the detection of growth in the blood culture bottles. The bottles 
are then removed from the system and the process of identification and antimicrobial 
susceptibility testing of microorganisms is initiated.  
The third and the last section is the post-analytical part. In this final step, the microbiological 
diagnosis is reported to the clinic where the antimicrobial treatment of patients is started or 
adjusted accordingly.   
The main goal of microbiological diagnostics is to obtain reliable and rapid information on 
the identity and the susceptibility profile of the microorganism causing sepsis. Therefore 
improvement in all of the three steps is similarly essential for shortening the turn-around time 
until reliable results can be obtained.  
However, the characteristics of these three parts are significantly different from each other. 
The pre-analytical part is mostly hospital or laboratory specific, e.g. transport times of blood 
cultures differ significantly among laboratories and the improvements in shortening the 
transport time are mostly center-specific (Ronnberg et al., 2013).  
Likewise the post-analytical steps are generally hospital and laboratory specific, e.g. reporting 
of positive blood cultures differ significantly between countries and centers.  
In contrast, improvements regarding the analytical part may be implemented in different 
laboratories and geographical regions independently of the pre- and post-analytical processes. 
Therefore the analytical part has been the focus for scientific and clinical research during the 
recent years. 
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Table 2 The major steps in microbiological diagnosis of sepsis. 
Pre analytical Analytical Post analytical 
Meeting the patient Removing positive BC 
bottles from the system 
 
Clinical diagnosis of 
sepsis 
Gram staining Report Gram-staining 
results and start/adjust 
antimicrobial therapy 
Collecting BC Identification  from BC 
bottles 
Report rapid ID result 
Sending BC bottles to 
the laboratory 
Subculture of bottles onto 
plates 
 
Place the BC bottles 
into BC system 
Growth of bacteria on agar 
plats 
 
 Conventional ID and 
susceptibility testing 
Report rapid ID result 
and adjust 
antimicrobial therapy 
In comparison to the other two parts, the analytical part of microbiological diagnostics 
significantly improved during the last decade. The introduction of state of the art commercial 
methods and development of reliable and rapid in-house methods suitable for clinical routine 
has opened a new era in clinical microbiology.  
However, as all other improvements in clinical medicine, information and know-how 
regarding the performance of these novel methods is decisive for their implementation into 
clinical routine. Today, there is still limited information on the analytical and clinical 
performance of a number of modern microbiological methods.   
1.8 IDENTIFICATION OF MICROORGANISMS 
1.8.1 Culture-independent methods 
As the name describes, the goal of culture-independent methods is to bypass the long process 
of blood cultures and subsequent cultures. In this approach blood sample from the patients 
will be analyzed directly and the results on detection, identification and hopefully 
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susceptibility profile of the microorganisms causing sepsis will be available in a couple of 
hours. The clinical effect of this approach in patients with sepsis will probably be very 
positive since the turn-around time is significantly shorter than for culture-dependent 
methods. 
Recent improvements in molecular microbiology provided methods that have been tested in 
clinical studies. Hitherto, there are five systems developed for broad range detection of 
microorganisms directly from blood (Table 3).  
However, preliminary experiences showed limited sensitivity and specificity, and in 
combination with the high cost per sample the clinical usage of these methods in routine 
microbiological diagnostics has been very restricted. 
The major challenge in the approach to detect microorganisms directly from blood samples is 
the minute amount of microorganisms in combination with high amounts of human DNA and 
other hematogen molecules (Opota et al., 2015b).  
This requires high sensitivity in the presence of multiple substances which may interfere with 
the reaction and may lead to inconclusive results. 
Table 3 The commercially available systems in culture-independent microbiological 
diagnostics of sepsis. 
System Manufacturer Method Total Coverage 
(bacteria and 
fungi + resistance 
marker) 
Turnaround 
time (hours) 
SepsiTest 
 
Molzym, Bremen,  
Germany 
Broad-range PCR 
+ sequencing 
>345 6 
SeptiFast 
 
Roche Molecular 
System,  
Basel, Switzerland 
Multiple broad-
range 
real-time PCR 
21 
+ mecA 
3.5-5 
MagicPlex 
 
Seegene, Seoul, 
Korea 
Multiple PCR + 
multiplex real-
time PCR 
117 
+ mecA, vanA/B 
3-5 
VYOO 
 
SIRS-Lab, Jena, 
Germany 
Multiplex PCR + 
electrophoresis 
39 8 
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IRIDICA 
(PLEX-ID)  
 
Abbott 
Molecular, 
Carlsbad, 
CA, USA 
Multiplex broad-
range 
PCR/electrospray 
ionization mass 
spectrometry 
>800 
+ mecA, vanA/B 
6 
 
1.8.2 Culture-dependent methods 
1.8.2.1 Conventional methods 
The gold standard method in the analytical part of microbiological diagnostics of sepsis is to 
identify microorganisms using phenotypic and biochemical tests. These methods require pure 
culture (at least isolated single colonies) on agar plates and are summarized as conventional 
methods. 
Obtaining pure cultures with visible singular colonies is a time consuming process that takes 
around 20 h. It can take up to 72 h for slow-growing microorganisms such as anaerobic 
bacteria. Next, the identification of microorganisms using conventional biochemical methods 
takes another 8 - 48 hours.  
The introduction of methods such as Matrix-Assisted Laser Desorption Ionization - Time of 
Flight (MALDI-TOF) and nucleic acid-based methods made it possible to shorten the time 
for identification of microorganisms from days to a couple of minutes. Indeed the 
identification of microorganisms with MALDI-TOF MS takes minutes including the hand-on 
time.  
The next step on improvement of identification of microorganisms is to focus on approaches 
bypassing the long period of sub-culture period. It is only possible by development and 
establishment of sub-culture independent microbiological methods. 
1.8.2.2 Rapid identification methods 
The rapid identification methods that will be described in this section are blood culture-
dependent but sub-culture independent.  
Currently, there are several different types of methods available for identification of 
microorganisms directly from blood culture bottles.  
These include multiplex PCR, MALDI-TOF MS and microarray and florescence in situ 
hybridization (Opota et al., 2015a). The characteristics of the commercially available 
methods are described in Table 4.  
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Table 4 The commercially available systems in blood culture-dependent microbiological 
diagnosis of sepsis. 
System Manufacturer Method Total Coverage 
(bacteria and 
fungi + resistence 
marker) 
Turnaround 
time (hours) 
FilmArray Idaho 
Technology, Salt 
Lake City, UT, 
USA 
Multiplex PCR 24 
+ mecA, vanA/B, 
KPC 
1 
MALDI-TOF 
MS 
Brucker Daltonics 
(Bremen, 
Germany) 
bioMérieux 
(Marcy l’Etoile, 
France) 
Mass-
spectrometry 
>5000 <1 
Prove-it Sepsis Mobidiag, 
Esbo, Finland 
Microarray 73 
+ mecA 
5 
Verigene 
(Gram-
negative/Gram-
postive) 
Nanosphere, 
Northbrook, 
IL, USA 
Microarray 12/8 
+ mecA, vanA/B 
/CTX-M, KPC, 
NDM, VIM, IMP, 
OXA 
2.5 
QuickFISH 
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The turn-around time for non-culture based methods and rapid identification methods are 
presented in Fig 4. 
 
Fig. 4 This figure was adopted from (Liesenfeld et al., 2014). 
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2 AIM OF THE PROJECT 
The overall aim of this doctoral project was to improve the microbiological diagnosis of 
sepsis by evaluating and extending the use of rapid methods in identification of 
microorganisms from blood cultures. 
 
Specific aims were to 
 
Paper 1 
Evaluate the clinical performance of FilmArray in identification of microorganisms from 
positive blood cultures collected prospectively.  
 
Paper 2 
Analyze the performance of FilmArray and MALDI-TOF MS in identification of 
microorganism’s blood cultures before the bottles signal positive in the BC systems. 
 
Paper 3 
Evaluate the performance of (i) four different blood culture bottles and two different blood 
culture systems in detection and time to detection of anaerobic bacteria and (ii) the 
performance of MALDI-TOF MS in identification of anaerobic bacteria from different bottle 
types. 
 
Paper 4 
Asses the performance of FilmArray and MALDI-TOF MS for identification of 
microorganisms from BC bottles with polymicrobial growth. 
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3 MATERIALS AND METHODS 
The studies were performed at Karolinska University Laboratory in Huddinge, Sweden, that 
serves the southern part of the greater Stockholm area and surrounding cities and suburbs. 
The laboratory receives BC samples from three tertiary-care hospitals: Karolinska University 
Hospital in Huddinge, Stockholm, Södertälje Hospital in Södertälje and South General 
Hospital, Stockholm, with a total of 1,569 beds. 
3.1 BLOOD CULTURE SYSTEMS AND BLOOD CULTURE BOTTLES 
The BC systems employed in the studies were the BacT/Alert 3D (bioMérieux, Marcy 
l'Etoile, France) and the BD Bactec 9240 (Becton Dickinson Instrument Systems, Sparks, 
MD) BC systems. The BacT/Alert 3D BC system was used with aerobic BacT/Alert FA Plus 
(resin-based), anaerobic BacT/Alert FN (charcoal-based) and FN Plus (resin-based), and 
pediatric BacT/Alert PF Plus BC bottles (resin-based), containing non-specific media for the 
detection of yeasts, aerobic and aerobic bacteria.  
The BD Bactec 9240 BC system was used with Bactec Mycosis IC/F BC bottles (resin-
based) for selective culture and recovery of yeast, and Bactec Plus (resin-based) and Bactec 
Lytic BC bottles (no absorbents) for cultivation of anaerobic bacteria (Table 5). As for 
clinical routine practice, BC bottles were incubated until they signaled positive or for a 
maximum of five days. 
Table 5 BC bottles and BC systems used in the studies. 
Study 
BacT/Alert BC system BD Bactec BC system 
FA Plus FN Plus FN PF Plus 
Mycosis 
IC/F Plus Lytic 
1 × ×  × ×   
2 × ×      
3  × ×   × × 
4 × ×  ×    
 
3.2 CLINICAL BLOOD CULTURES 
All patient samples were obtained from BC samples arriving at the Karolinska University 
Laboratory for routine microbiological diagnostic. 
In Paper 1, a total of 206 BC bottles including Bactec Mycosis IC/F BC bottles, BacT/Alert 
FA Plus, BacT/Alert FN Plus and BacT/Alert PF Plus BC bottles were investigated. Bottles 
were collected for analyses when they had signaled positive.  
In Paper 2, BacT/Alert FA Plus and BacT/Alert FN Plus BC bottles were analyzed a) prior to 
BC positivity and b) prior to incubation. a) From a quadruplicate set of BC bottles, the fourth 
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BC bottle was analyzed before signaling for BC positivity, when the other three bottles had 
signaled positive. b) From a total of 400 BC bottles, an aliquot was taken prior to incubation 
and stored frozen. The pre-incubation broth from BC bottles which later on signaled positive 
was then thawed and analyzed. 
In Paper 4, a total of 48 BC bottles BacT/Alert FA Plus and BacT/Alert FN Plus with 
polymicrobial growth as judged by Gram stain were included. Another 134 BC bottles were 
used to prepare 67 simulated polymicrobial samples by mixing equal volumes of broth from 
each bottle. In total, 115 polymicrobial samples were analyzed. 
3.3 SIMULATED BLOOD CULTURES 
Simulated BC bottles were prepared by inoculation of a defined number of bacteria into BC 
bottles together with defibrinated horse blood. Bacteria from frozen stocks were cultured on 
blood agar plates in appropriate atmosphere at 36°C for 24 h (aerobe bacteria) or 48 h 
(anaerobe bacteria). Colonies from agar plates were suspended in 0.01 M phosphate buffered 
saline (pH 7.3-7.4) to 0.5 McFarland (1.5×10
8
 CFU/ml), diluted and added to a BC bottle. 
Aliquots of the suspension were cultured on blood agar plates to control the bacterial density 
in the final inoculum. 
In Paper 2, four clinical isolates of each S. aureus and E. coli, and two reference strains, S. 
aureus ATCC 29213 and E. coli ATCC 25922 were analyzed in BacT/Alert FA Plus BC 
bottles. Each bottle was inoculated with 1000 CFU in 100 µl buffer and 10 ml horse blood. 
In Paper 3, 100 isolates of anaerobe bacteria were analyzed in BacT/Alert FN and FN Plus 
BC bottles incubated in the BacT/Alert 3D BC system and in Bactec Plus and Bactec Lytic 
BC bottles incubated in the Bactec 9240 BC system. Each bottle was inoculated with 750 
CFU in 50 µl buffer and 5 ml horse blood. 
3.4 THE FILMARRAY BCID ASSAY 
The FilmArray Assay (BioFire, Salt Lake City, UT) is a closed in vitro diagnostic system for 
the detection of bacterial and fungal pathogens. The FilmArray blood culture ID (BCID) 
panel covers 19 bacterial targets and 5 Candida species as well as three antimicrobial 
resistance genes (Table 6).  
The analysis was performed following the manufacturer’s recommendations. Briefly, 1 ml 
hydration buffer was injected into the pouch using the FilmArray product syringe. Then, 100 
µl of the BC broth was diluted in 500 µl FilmArray dilution buffer, and 300 µl of the diluted 
sample was injected into the FilmArray pouch before loading on the FilmArray system for 
analysis. DNA extraction, amplification, detection of the target and melt curve analysis of the 
amplification product are automated within the system and results are provided by the 
software automatically within 60 min.  
  
17 
 
Each pouch includes two internal run controls for both the primary amplification and the 
analyze-specific detection stages.  
Results of the assay are provided by the software only if the quality control reactions are 
appropriately detected. When either of the two controls fails, the result is listed as invalid. 
Table 6 The FilmArray BCID panel. 
Category Target 
Gram-negative bacteria Enterobacteriaceae 
 Escherichia coli 
 Enterobacter cloacae complex 
 Klebsiella oxytoca 
 Klebsiella pneumoniae 
 Serratia marcescens 
 Proteus species 
 Acinetobacter baumannii 
 Haemophilus influenzae 
 Neisseria meningitidis 
 Pseudomonas aeruginosa 
Gram-positive bacteria Staphylococcus species 
 Staphylococcus aureus 
 Streptococcus species 
 Streptococcus agalactiae 
 Streptococcus pyogenes 
 Streptococcus pneumoniae 
 Enterococcus species 
 Listeria monocytogenes 
Fungi Candida albicans 
 Candida glabrata 
 Candida krusei 
 Candida parapsilosis 
 Candida tropicalis 
Antibiotic resistance markers mecA 
 vanA/vanB 
 blaKPC 
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3.5 DIRECT MALDI-TOF MS 
MALDI-TOF MS was performed directly from BC bottles, omitting subculture on solid 
media. An in-house protocol with slight modifications between the studies was used. In 
general, 1.5-5 ml BC broth was first centrifuged for 5-10 min at low speed (110-180 rcf) to 
remove larger particles.  
The supernatant was then transferred to an Eppendorf tube and centrifuged for 2 min at high 
speed (20,800 rcf) to collect the microorganisms. The pellet was washed with molecular-
grade water; in Paper 4, additional washing steps with saponin (0.01% in water) and 
ammonium chloride were performed for more efficient removal of interfering blood 
components. Proteins were extracted by exposing the pellet to organic acid (50% acetonitrile, 
47.5% water, 2.5% trifluoracetic acid) and 70% formic acid.  
After centrifugation at high speed, the supernatant was spotted on a steel 96-spot MALDI 
target plate (Bruker Daltonics, Bremen, Germany). In some cases, extraction was performed 
directly on the MALDI target plate using 70% formic acid. The sample was allowed to dry 
before application of 1 µl alpha-cyano-4-hydroxycinnamic acid matrix and analysis with the 
MALDI-TOF MS (Bruker Daltonics, Bremen, Germany).  
The Bruker Biotyper 3.0 software and library (Bruker Daltonics) were used for spectra 
analysis. Scores of >2.0 were considered identification at the species level and scores of >1.7 
were considered identification at the genus level, according to the manufacturer’s 
recommendation. 
3.6 CONVENTIONAL METHODS FOR IDENTIFICATION OF 
MICROORGANIMS 
Gram stains were done directly from positive BC bottles. According to the results of the 
staining, the broth was cultured on relevant agar plates. Microorganisms grown on the agar 
plates were identified by MALDI-TOF MS (Bruker Daltonik) or Vitek2 XL (bioMérieux, 
France). Validated desktop spot tests, including catalase, oxidase, indole spot and L-
pyrrolidonyl-β-naphthylamide, were performed as indicated. In case of discrepant results 
between the study methods and conventional methods, additional subcultures were performed 
on appropriate selective media.  
3.7 PARTIAL 16S rRNA GENE SEQUENCING  
In Paper 3, partial 16S rRNA sequencing, including the hypervariable regions V3 and V4, 
was performed in cases of discrepant results from direct MALDI-TOF MS and previous 
bacterial identification by conventional methods. Bacterial DNA was extracted using the 
automated Biorobot M48 system (Qiagen, Hilden, Germany) according to the manufacturer’s 
instructions. PCR amplification was performed by adding 3 μl of the extract to a master mix 
containing 10 μM of each primer (5´-CGGCCCAGACTCCTACGGGAGGCAGCA-3´ and 
5´-GCGTGGACTACCAGGGTATCTAATCC-3´) together with 25 μl HotStarTaq master 
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mix (Qiagen) to give a final volume of 50 μl. After initial denaturation, the cycling 
parameters were 32 cycles at 94°C for 30 s, 56°C for 30 s, and 72°C for 1 min, followed by a 
final extension at 72°C for 7 min.  
The PCR products were purified using chemical purification (PE Applied Biosystems) 
according to the manufacturer's instructions. Sequencing of both strands was carried out 
using an ABI Prism Big Dye Terminator v3.1 cycle sequencing kit (Applied Bio systems, 
Foster City, CA) with a Gene Amp 9700 thermocycler (Applied Biosystems). Sequencing 
primers used in the two reactions were 5’-AGAGTTTGATCMTGGCTCAG-3’ and 5’-
GWATTACCGCGGCKGCTG-3’, 1μM each.  
The sequence cycling products were analyzed by capillary electrophoresis and fluorescence 
detection with an Applied Biosystems ABI 3100 genetic analyzer. The fluorescence data 
were analyzed with the SeqScape Software program (version 4.5; Gene Codes Corporation, 
Ann Arbor, MI). A BLAST search was run on the obtained sequences to determine bacterial 
identity. 
3.8 STUDY PROTOCOL 
3.8.1 Paper 1 
The study was performed prospectively on BC bottles received between April 2013 and June 
2013 for routine microbiological diagnostic at the Karolinska University Laboratory. Only 
one sample per patient was used. Due to interference with downstream applications, only 
resin-based BC bottles were included. BC bottles were analyzed after yielding a positive 
signal in the BC system. Microorganisms were identified using the FilmArray Assay BCID 
panel. Conventional identification methods served as reference method in this study. 
3.8.2 Paper 2 
The performance of the FilmArray Assay and direct MALDI-TOF MS was analyzed in 
identification of bacteria and yeast from BC bottles prior to positivity in the BC system in 
different settings. Simulated BC bottles were used to investigate the performance of the two 
methods in relation to incubation time in the BC system (after 2.5 h, 5 h and 7.5 h), with and 
without a simulated transport time (2.5 h RT).  
The influence on assay performance by transport time without further incubation in the BC 
system was investigated by incubation of BC bottles at RT (2.5 h, 8 h and 24 h). To 
investigate the assay performance on clinical BC bottles prior to incubation in the BC system, 
a 2-ml aliquot was removed from BC bottles upon arrival in the laboratory and stored frozen 
until the corresponding bottle yielded a positive signal. Alternatively, one BC bottle from a 
quadruplicate set of bottles was analyzed after partial incubation (prior to positivity). The 
time point for analysis of the fourth bottle was determined as the time when the third bottle of 
the set had reached positivity. 
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3.8.3 Paper 3 
A collection of 100 anaerobic bacteria isolated from positive BC bottles at Karolinska 
University Hospital, Huddinge, Sweden and stored at -70C was used in this study. From 
each isolate, simulated BC bottles were prepared to compare four different types of BC 
bottles for the recovery of anaerobic bacterial species in two different types of BC systems. 
Detection rates, time to detection and the performance of direct MALDI-TOF MS for 
bacterial identification was determined and compared between the BC bottle types.  
3.8.4 Paper 4 
The study was performed prospectively on BC bottles received between September 2015 and 
December 2015 for routine microbiological diagnostic at the Karolinska University 
Laboratory. Positive BC bottles with polymicrobial growth as judged by Gram stain were 
included. In addition, simulated polymicrobial BC samples were prepared from two positive 
clinical BC bottles. All polymicrobial BC samples were analyzed by FilmArray with the 
BCID panel and direct MALDI-TOF MS. Conventional culture-based isolation and 
identification methods were used as reference method for comparison. 
3.9 STATISTICAL ANALYSIS 
The Fisher’s exact test and the Chi-square test was used to compare detection rates between 
two or more different BC bottle types, respectively (Paper 1 and Paper 3). The Wilcoxon 
matched-pairs signed-rank test was used to compare time to detection for different BC bottles 
(Paper 3). Differences with p-values <0.05 were considered statistically significant. 
3.10 ETHICAL PERMISSION 
An ethical permission was not required because no patients’ data were included in all studies.  
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4 RESULTS 
4.1 MICROORGANISMS AND BLOOD CULTURES 
In Paper 1, a total of 206 blood culture bottles were studied. Only one blood culture per 
patient was included in the prospective evaluation of the FilmArray BCID panel. There were 
167 BC with monomicrobial growth and 24 positive BC with polymicrobial growth.  In 12 
samples, Gram staining and subcultures were negative although the bottles signaled positive 
in the BC system. The FilmArray results were invalid in 3/206 (1.5%) bottles; these samples 
were excluded from further evaluation. Fig 5 depicts the study design.   
 
Fig. 5 FilmArray BCID evaluation schemes (N represents number of BC bottles tested). 
Conventional microbiology methods were used as reference methods. 
During the study period 35 different species were identified by conventional methods, 24/35 
(69%) covered by the FilmArray BCID panel. The three Enterococcus species; Enterococcus 
faecalis, Enterococcus faecium, and Enterococcus avium were identified at the genus level.  
Among the 191 positive BC bottles with growth, 175 (91.6%) contained microorganisms that 
were included in the FilmArray BCID panel.  
In Paper 2, both clinical and simulated BC bottles were investigated. In total, 30 simulated 
BC bottles and 800 clinical samples were included in the study. Samples from 400 clinical 
BC bottles were collected in order to evaluate the performance of the FilmArray BCID 
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panel for identification of microorganisms prior to incubation in the BC system. Sixteen of 
these 400 BC bottles signaled positive for growth and were analyzed.  
In addition, 400 BC bottles from quadruplicate BC samples were investigated in order to 
analyze the performance of the FilmArray assay after incubation but prior to signaling 
positive in the BC system. Twenty-three of these bottles were analyzed in this study, as 
soon as the other three bottles taken from the same patient signaled positive. Fifteen of 23 
(65%) bottles later became positive within 5-day incubation period, and 8/23 (35%) 
remained BC-negative. All of the thirteen different species that were identified from clinical 
BC bottles were included in the FilmArray BCID panel. 
In Paper 3, a total of 100 anaerobic bacteria that were previously isolated from positive 
blood cultures were included in the study. The isolates are presented in Fig 6.  
All of the isolates were included in the MALDI-TOF MS database applied in the study. These 
isolates were used to prepare 400 simulated BC samples. 
 
Fig. 6 Anaerobic blood culture isolates diversity. 
In Paper 4, 32 different types of microorganisms were identified during the study period (Fig 
7). The total coverage rate of all microorganisms in the sample material by the FilmArray 
BCID panel was 96.0% (243/253). 
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Fig. 7 Clinical isolates diversity. Miscellaneous species* include one of each Salmonella 
typhi, Streptococcus pneumoniae, Micrococcus luteus, Enterococcus avium, Bacillus cereus, 
Acinetobacter pitii, Clostridium ramosum, Gram-negative anaerobes, Clostridium species, 
Bacillus species, Group G streptococcus, Gram-positive cocci and Candida glabrata. 
4.2 IDENTIFICATION BY FILMARRAY FROM BC BOTTLES 
In Paper 1, monomicrobial growth was observed in 167/191 (87.4%) BC bottles. 
Identification of the microorganism by FilmArray was successful in 153/167 (91.6%) BC 
bottles. Importantly, the detection rate for microorganisms covered by the FilmArray BCID 
panel was 153/154 (99.4%). In the remaining sample, a coagulase-negative staphylococcus 
(CoNS) could not be identified.  
Interestingly, FilmArray identified an additional microorganism in 6/167 (3.6%) BC bottles 
that was not detected by conventional methods.  
In four BC bottles with CoNS and in one bottle with S. pneumoniae, the FilmArray assay 
simultaneously detected an Enterococcus isolate. In another BC bottle with Candida 
glabrata, FilmArray detected also Candida albicans (Table 7).  
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Table 7 Identification of bacteria and yeasts from monomicrobial BC by FilmArray. 
 
In 24/191 (12.6%) positive BC, growth of more than one microorganism was detected by 
conventional methods. FilmArray could identify all microorganisms in 17/24 (71%) samples. 
In 6/24 (25%) polymicrobial cultures, FilmArray could not detect any of the microorganisms 
detected by conventional methods.  
In contrast, in one BC bottle with CoNS and alpha-hemolytic streptococci, FilmArray 
detected an Enterococcus isolate in addition (Table 8). 
Identification 
BC and 
FA 
positive 
BC positive 
and FA 
negative 
BC negative 
and FA 
positive 
Microorganisms included in FA BCID     
Gram-negative    
Escherichia coli  34   
Klebsiella pneumoniae  5   
Klebsiella oxytoca  2   
Proteus mirabilis  2   
Pseudomonas aeruginosa  2   
Haemophilus influenza 2   
Enterobacter cloacae  1   
Enterobacter aerogenes 1   
Salmonella species   1   
Serratia marcescens  1   
Neisseria meningitides 1   
Gram-positive     
Coagulase negative staphylococci 37 1  
Staphylococcus aureus  19   
Streptococcus pneumoniae    13   
Enterococcus species       9   4 
Streptococcus agalactiae 5   
Alpha-hemolytic streptococci 4   
Streptococcus pyogenes 2   
Listeria monocytogenes    2   
Fungi     
 Candida albicans     6  1 
Candida glabrata      4   
Microorganisms not included in FA BCID     
Micrococcus species      3 3  
Corynebacterium species   2 2  
Peptoniphilus species 2 2  
Capnocytophaga canimorsus 1 1  
Bacteroides fragilis 1 1  
Eggerthella lenta 1 1  
Gemella species 1 1  
Lactobacillus species 1 1  
Parvimonas micra 1 1  
Antibiotic resistance markers    
MecA  15 1 3 
VanA/VanB 0  0 
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It was not possible to detect the isolates that were only identified by FilmArray even after 
repeated sub-cultures from these bottles. These results were therefore interpreted as false 
positive results. 
Table 8 Identification 24 polymicrobial blood cultures by FilmArray. 
 
Identification ID by 
Culture  
ID by 
FA 
E. faecium + (CoNS) 1/1 1/1 
E. coli  +  K. pneumonia 1/1 1/1 
C. albicans + E. faecalis 1/1 1/1 
E. cloacae+E. faecium 1/1 1/1 
E. faecalis+P.aeruginosa 1/1 1/1 
E. faecium  + alpha streptococci 1/1 1/1 
E. faecium + CoNS 1/1 1/1 
E.coli + alpha streptococci 1/1 1/1 
E.coli + K. pneumoniae  1/1 1/1 
E. coli + alpha streptococci 1/1 1/1 
K. oxytoca + E.faecium 1/1 1/1 
S. species + alpha streptococci 1/1 1/1 
Staphylococcus aureus  +  CoNS 1/1 1/1 
S. aureus + alpha streptococci 1/1 1/1 
S. aureus+P. aeruginosa 1/1 1/1 
CoNS + alpha streptococci 1/1 1/1 
S. pyogenes + E. faecalis 1/1 1/0 
CoNS + E. faecalis 1/1 1/0 
E.coli + B. fragilis 1/1 0/X 
P. acnes + Micrococcus species 1/1 X/X 
E.coli+ K. pneumoniae + E. avium 1/1/1 1/1/1 
CoNS + alpha streptococci + 
Enterococcus  
1/1/0 1/1/1 
K. pneumoniae + C. perfringens + 
alpha streptococci 
1/1/1 1/X/0 
S. pneumoniae + CoNS + Bacillus 
species 
1/1/1 1/1/X 
Antibiotic resistance markers   
MecA 5 5 
VanA/VanB 0 0 
  
Overall, FilmArray could identify all microorganisms in 170/175 (97.1%) BC positive for 
microorganisms those were included in the FilmArray BCID panel. 
In Paper 2, in simulated BC bottles, the FilmArray identified 9/10 isolates after 5 h, and the 
remaining one E. coli isolate after 7.5 h of incubation in the blood culture system (Table 9). 
Interestingly, the median TTD of growth for the BC bottles in the automated BC system was 
11.1 h (range, 9.12 to 25 h).  
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Thus, FilmArray was able to detect bacteria just before samples had been incubated for 
approximately half of the time to signal positivity in BC system. In order to measure the 
effect of transport time on FilmArray sensitivity, the bottles were kept at RT for 2.5 h before 
loading in the BC system. Interestingly, microorganisms in 6/10 (60%) simulated bottles 
could be identified by the FilmArray already after 2.5 h of incubation in the blood culture 
system (Table 9).  
The remaining four samples (two each of S. aureus and E. coli) were identified after 5 h of 
incubation in the BC system. The median TTD in the BC system was 9.1 h (range, 8.2 to 10.8 
h). The positive results with the first two sets of experiments encouraged us to test the 
possibility of identification of microorganisms from bottles prior to incubation in the blood 
culture system but with simulated transport time only. Interestingly FilmArray could identify 
microorganisms in 9/10 (90%) bottles 8 h of incubation at RT. 
Table 9 In vitro study results from BC bottles inoculated with Escherichia coli (n=5) and 
Staphylococcus aureus (n=5). At specified time points in the BC system, BC broth was 
aspirated and subjected to testing with FilmArray and MALDI-TOF MS. Once a positive 
result was obtained, no additional testing with the same method was performed.   
 
Time in blood 
culture system 
Direct incubation in the blood culture system  Blood culture system after 
incubation at RT for 2.5 h 
No of bottles  
with E. coli  
No of bottles  
with  S. aureus 
No of bottles  
with E. coli 
No of bottles  
with  S. aureus 
FilmArray MALDI- 
TOF 
FilmArray MALDI- 
TOF 
FilmArray FilmArray 
2.5 h 0 0 0 0 3 3 
5 h 4 0 5 0 2 2 
7.5 h 1 0 NA 0 NA NA 
Until signaling 
positive 
NA 5 NA 5 NA NA 
 
Similarly, the clinical samples were tested by FilmArray prior to culture positivity. In total, 
23 blood culture bottles were analyzed. Fifteen of 23 (65%) bottles signaled positive in the 
culture system while 8/23 (35%) remained negative after 5 days of incubation.  
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The FilmArray could identify 14/15 (93%) microorganisms in positive bottles prior to 
detection in the BC system (Table 10). The only FilmArray-negative and BC-positive sample 
was one S. pneumoniae isolate that signaled positive after 74 h in the BC system. Eight BC 
bottles that did not signal positive until the end of the incubation time of 5 days in the BC 
system were also negative in the FilmArray analysis. 
Then, the performance of the FilmArray assay in identification of microorganisms from BC 
bottles before incubation in the BC system was studied. Sixteen positive BC bottles were 
analyzed. The microorganisms in five samples were directly identified by the FilmArray. 
These were one each of E. coli, Streptococcus pyogenes, S. pneumoniae, and Candida 
albicans and one polymicrobial BC containing Klebsiella oxytoca and Citrobacter freundii. 
Broth from the remaining 11 samples was centrifuged, and the pellet was analyzed with the 
FilmArray. The FilmArray then identified microorganisms in an additional three samples, 
each containing S. aureus. In total, 8/16 (50%) samples were correctly identified by the 
FilmArray (Table 11).  
Four blood culture bottles that did not signal positive until the end of the incubation time of 5 
days in the BC system were also negative on the FilmArray analysis. 
Table 10 The identification of microorganisms by FilmArray during incubation in the BC 
system before detection. 
   No FilmArray results  Standard method results  
FilmArray positive/ 
Culture positive  
14        
 4/4 
Staphylococcus aureus Staphylococcus aureus 
   4/4  Staphylococcus spp. + MecA  Staphylococcus epidermidis  
   1/1  Staphylococcus spp. + MecA  Coagulase negative staphylococci  
   1/1  Enterococcus spp. Enterococcus faecium  
   1/1  Enterococcus spp. Enterococcus faecalis  
 2/2 
Eschericha coli Eschericha coli 
   1/1 Klebsiella pneumoniae  Klebsiella pneumoniae   
FilmArray negative/ 
Culture positive  
1/1     No detection   Streptococcus pneumoniae 
FilmArray negative/ 
Culture negative  
8/8 No detection   No growth (5 days)   
Total  23 
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Table 11 Identification of microorganisms by FilmArray before incubating the bottles in 
the blood culture system. 
   No FilmArray Standard methods 
FilmArray positive/Culture 
positive  8/16   
  
Klebsiella oxytoca + 
Enterobacteriacea 
Klebsiella oxytoca + 
Citrobacter freundii 
  Streptococcus pneumoniae Streptococcus pneumoniae 
    
Staphylococcus aureus Staphylococcus aureus 
    
Staphylococcus aureus Staphylococcus aureus 
    
Staphylococcus aureus Staphylococcus aureus 
    Streptococcus pyogenes Streptococcus pyogenes 
    Escherichia coli Eschericha coli 
    Candida albicans Candida albicans 
FilmArray negative/ 
Culture positive  8/16   
      Not detected 
Eschericha coli + Streptococcus 
spp. 
      Not detected Staphylococcus epidermidis 
      Not detected Staphylococcus aureus 
      Not detected Enterococcus faecalis 
      Not detected Klebsiella pneumoniae 
      Not detected Klebsiella pneumoniae 
      Not detected 
Escherichia coli 
      Not detected 
Escherichia coli 
FilmArray 
negative/Culture negative  4/4 Not detected No growth (5 days) 
In Paper 4, the FilmArray assay could identify 230/253 (90.9%) microorganisms from BC 
bottles with polymicrobial growth.  
Considering the microorganisms included in the FilmArray BCID panel, the assay could 
detect and identify 230/243 (94.7%) of the isolates (Fig. 8). If a BC bottle is interpreted as an 
episode, the FilmArray could correctly identify all microorganisms in 99/115 (86.1%) of 
episodes (Table 12).  
In clinical polymicrobial samples, FilmArray identified both microorganisms in 29/36 (81%) 
BC bottles with two microorganisms and one of two in seven BC bottles. All microorganisms 
were identified in 9/12 (75%) BC bottles with growth of three microorganisms and in 3/12 
(25%) BC bottles, FilmArray could not identify any of the microorganisms detected by 
conventional methods. 
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Among species covered by the BCID panel, the assay missed 10 CoNS (five Staphylococcus 
epidermidis, two Staphylococcus hominis and one of each Staphylococcus sciuri, 
Staphylococcus capitis, Staphylococcus warner) two alpha-streptococci (one of each 
Streptococcus anginosus and Streptococcus oralis), and Enterococcus faecalis compared to 
conventional culture-based methods (Fig. 9). 
 
Fig. 8 Identification of microorganisms from blood culture bottles with polymicrobial growth 
using FilmArray, MALDI-TOF MS and conventional laboratory methods. 
Table 12 Detection of microorganisms using FilmArray, direct MALDI-TOF MS with 
conventional laboratory methods. 
No. isolate Microorganism Culture 
results (no.) 
FA BCID 
results (no.) 
MALDI-TOF 
results (no.) 
  Gram positive    
1 54 CoNS* 54 44
 g
 11 
2 20 Alpha streptococcus* 20 18
 g
 No ID 
3 16 Enterococcus faecalis 16 15
 g
 5 
4 22 Staph aureus 22 22 16 
5 7 Enterobacter cloacae 7 7 1 
6 5 Streptococcus pyogenes 5 5 1 
7 5 Enterococcus faecium 5 5
 g
 2 
8 5 Acinetobacter baumannii 5 5 No ID 
9 3 Streptococcus agalactiae 3 3 1 
10 2 Enterococcus gallinarum 2 2
 g
 No ID 
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11 1 Bacillus species 1 x⃰ No ID 
12 1 M. Luteus 1 x⃰ No ID 
13 1 S. Typhi 1 1
 g
 No ID 
14 1 Streptococcus pneumoniae 1 1 1 
15 1 Enterococcus avium 1 1
 g
 No ID 
16 1 Bacillus cereus 1 x⃰ No ID 
17 1 Acinetobacter pitii 1 x⃰ No ID 
18 1 Gram positive cocci 1 x⃰ No ID 
19 1 Group G streptococci 1 1
 g
 No ID 
  Gram negative    
20 50 E. coli 50 50 16 
21 19 Klebsiella pneumoniae 19 19 10 
22 8 Klebsiella oxytoca 8 8 2 
23 5 Pseudomonas aeruginosa 5 5 No ID 
24 2 Serratia marcescens 2 2
 g
 No ID 
25 3 Proteus mirabilis 3 3
 g
 No ID 
  Yeast    
26 12 Candida albicans 12 12 No ID 
27 1 Candida glabrata 1 1 No ID 
  Anaerobic    
28 2 Bacteroides fragilis 2 x⃰ No ID 
29 1 Clostridium  ramosum 1 x⃰ No ID 
30 1 Gram negative anaerobe 1 x⃰ No ID 
31 1 Clostridium species 1 x⃰ No ID 
 253 Total 253 230 66 
N, detection of microorganism to species level; Ng, detection of microorganisms to genus 
level; 0, failure to detect microorganisms; X, the microorganism that are not included in the 
panel. CoNS* includes (37 S. epidermidis, 9 S. hominis, three of each S. capitis and S. 
warneri and one of each S. haemolyticus and S. sciuri). Alpha streptococcus* includes (7 S. 
anginosus, 3 S. salivarius, 3 S. mitis, 2 S. Sanguinis and one of each S. gallolyticus, S. 
oralis, S. pyogenes, S. parasanguinis, S. cristatus). 
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Fig. 9 Microorganisms not identified by the FilmArray (n=13). 
4.3 IDENTIFICATION BY MALDI-TOF MS FROM BLOOD CULTURE BOTTLES 
In Paper 2, MALDI-TOF MS could not identify any of the 10 strains (five S. aureus and four 
E. coli) from the bottles after 8 h of incubation in the blood culture system. In contrast, all 10 
microorganisms could be identified by the method after the BC bottles signaled positive in 
the system. The method was not tested further for identification of microorganisms from 
bottles prior to BC positivity.  
In Paper 3, the influence of different anaerobic BC bottles on the performance of bacterial 
identification by direct MALDI-TOF MS was investigated. MALDI-TOF MS could 
accurately identify anaerobic bacteria in 51/67 (76%) from BacT/ALERT FN, 51/67 (76%) 
from BacT/ALERT FN Plus, 53/67 (79%) from BACTEC Plus and 50/67 (75%) from 
BACTEC Lytic bottles (Fig. 10). There was no difference in identification of anaerobic 
bacteria by MALDI-TOF MS among the four BC bottles included in the study. 
10 
2 
1 CoNS (5 S. epidermidis, 2 S.
hominis, 1 S. sciuri, S. capitis, 1 S.
warneri).
Alpha streptococcus (1 S. anginosus,
1 S. oralis).
Enterococcus faecalis
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Fig. 10 Identification of anaerobic bacteria directly from blood culture bottles by MALDI-
TOF MS. 
In Paper 4, MALDI-TOF MS could identify all microorganisms in only 2/115 (1.7%) BC 
bottles with polymicrobial growth. The method could identify one of two or more 
microorganisms in 66/115 (57%) blood culture bottles.  
4.4 DETECTION OF MEC A, VAN A AND VAN B AND blaKPC 
In Paper 1, in BC with monomicrobial growth, consistent results between conventional 
methods and FilmArray were obtained for one MRSA isolate and 14 methicillin-resistant 
CoNS. In contrast, three methicillin-susceptible CoNS were tested mecA-positive in the 
FilmArray. In order to evaluate the mecA result, conventional mecA PCR was performed. 
The PCR result confirmed the presence of mecA in 1/3 CoNS, whereas 2/3 were mecA 
negative, in line with the methicillin-susceptible phenotype. Regarding the BC bottles with 
polymicrobial growth, there were 5 methicillin-resistant Staphylococcus species that were 
detected both by disc diffusion and FilmArray.  
In addition, in one sample with S. aureus and CoNS, the FilmArray detected mecA without 
being able to distinguish MRSA or MSSA in the sample. Subsequent phenotypical tests 
later determined that the S. aureus isolate was MSSA and the CoNS were methicillin 
resistant. There was no microorganism that was vanA or vanB-positive. Similarly, no 
carbapenem-resistant or blaKPC-positive isolate was detected in the studied material. 
In Paper 4, the FilmArray detected mecA in 23 BC bottles (2 MRSA and 21 methicillin-
resistant CoNS) which was confirmed by conventional methods. 
76 % 
76 % 
79 % 
75 % 
0 20 40 60 80 100
BacT/ALERT FN
BacT/ALERT FN plus
Bactec plus
Bactec lytic
% 
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4.5 TURN-AROUND-TIME  
During the period of study 1, 2 and 4, the same FilmArray BCID instrument was used. The 
FilmArray is a fully automated system requiring a maximum of five min hands-on time. The 
total time from start to the identification result is 65 min for each sample. 
In study 2, 3 and 4, the turnaround time for direct MALDI-TOF MS was around 25 min with 
10 min hands-on time per one sample. 
4.6 TIME-TO-DETECTION  
For Paper 3, the shortest median TTD was 18 h in BACTEC Lytic followed by 
BacT/ALERT FN (23.5 h), BACTEC Plus (27 h) and BacT/ALERT FN Plus (38 h) bottles. 
There was a significant difference in the average TTD between the four bottle types included 
in the study (p<0.0001).  
The TTD was significantly shorter in BACTEC Lytic compared to BacT/ALERT FN, 
BacT/ALERT FN Plus and BACTEC Plus bottles (p<0.0001), similarly BacT/ALERT FN 
had shorter TTD than BACTEC Plus and BacT/ALERT FN Plus bottles (p<0.001 and p< 
0.0001 respectively). BACTEC Plus had shorter TTD than BacT/ALERT FN Plus bottles 
(p<0.0001) (Table 13). 
Table 13 TTD for all four types of anaerobic BC bottles. 
 
 
 
 
 
 
4.7 DETECTION OF GROWTH (PAPER 3) 
During the 5-day incubation, growth of anaerobic bacteria was detected in 89/100 (89%) 
BacT/ALERT FN, 80/100 (80%) BacT/ALERT FN Plus, 85/100 (85%) BACTEC Plus and 
94/100 (94%) BACTEC Lytic BC bottles. There was significant difference in the detection of 
anaerobic bacteria among the four bottle types studied (p<0.05).  
 
Time to detection 
BacT/Alert BACTEC 
FN FN Plus Plus Lytic 
Mean (h) (SD) 25.1(12.8) 38.5 (14) 30.9 (17.8) 19.9 (12.7) 
Median (h) 23.5 38 27 18 
Range (h) 10.6-61 14.9-61 9.1-101 7.3-46 
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BACTEC Lytic had a significantly higher detection rate than BacT/ALERT FN Plus 
(p<0.01). There was no significant difference in detection rates of anaerobic bacteria among 
the remaining bottle types (Fig. 11). 
 
Fig. 11 Overall growth of anaerobic bacteria in four different blood culture bottles. 
4.8 REPRODUCIBILITY TESTS (PAPER 1) 
Five positive BC, one of each with S. aureus, MRSA, CoNS, E. coli + alpha hemolytic 
streptococci, and E. coli + K. pneumonia, were tested with FilmArray BCID panel in 
duplicate. There was no difference between the two results showing that the FilmArray BCID 
method is reproducible. 
4.9 LONGITUDINAL FOLLOW UP WITH FILMARRAY (PAPER 1) 
When longitudinal follow-up of positive BC was considered, the FilmArray was positive for 
the correct pathogen at all time points, i.e., for S. aureus, E. coli, and CoNS (with mecA) on 
days 1, 7, 14, 21, and 28 and for C. glabrata and K. oxytoca on days 1, 2, 3, 4, 11, 17, and 21.  
4.10 PARTIAL 16S R RNA GENE SEQUENCING (PAPER 3) 
For paper 3, BLAST search showed 100% nucleotide identity to previously registered 
sequences of the 16S rRNA gene of Alistipes fingoldii (330/330 bases) and Parabacteroides 
goldsteinii (330/330 bases). Both species have been described as rare cause of sepsis, which 
were previously identified by the direct MALDI-TOF MS method. 
Number of BC bottles 
  
35 
 
5 DISCUSSION 
Sepsis is a devastating disease with global healthcare concerns and associated with both 
adverse clinical and economic outcomes. The mortality of sepsis is unacceptably high, even 
in today’s modern healthcare environments (Goto and Al-Hasan, 2013, Angus et al., 2001). 
Several studies have demonstrated that rapid administration of correct antimicrobial treatment 
is crucial for the survival of the patient (Kumar et al., 2006, Ferrer et al., 2014).  
Thus, receiving timely and actionable information from the laboratory on identification and 
antimicrobial susceptibility of the microorganism causing sepsis is crucial for patient 
management.  
Several studies have shown that the clinical implementation of rapid microbiological 
diagnostics of sepsis results in decrease in mortality, length of stay and health care costs and 
shorter time to appropriate antimicrobial therapy (Bauer et al., 2010, Huang et al., 2013). 
Currently, blood culture is the gold standard method for diagnosing sepsis. Blood cultures are 
sensitive, easy to perform and allow detection of viable microorganisms (Opota et al., 2015a). 
Until recently the identification of microorganisms from sub-cultures of the positive blood 
culture usually took between 24-72 hours.  
The introduction of MALDI-TOF MS in the clinical routine shortened this period to less than 
10 minutes. The next step in improvement of microbiological diagnostic of sepsis is therefore 
to bring solutions to bypass the subcultures that generally take between 20-72 h depending on 
the growth characteristics of the microorganism detected in blood cultures.     
The overall aim of this thesis was to evaluate and improve the use of rapid identification 
methods in identification of microorganisms directly from blood culture bottles. The rapid 
identification methods described in the present thesis refer to identification of 
microorganisms directly from blood culture bottles bypassing long sub-culture period of 20-
72h.  
There are several aspects of rapid microbiological identification methods that needs to be 
evaluated in order to implement the methods in the clinical routine and possibly to improve 
the use of these methods.    
The first prerequisite for rapid microbiological methods is to have a short turn-around time 
(TAT). It is reasonable to suggest that the results are ready in maximum 3-4 h after the blood 
culture bottle signals positive.  
Two methods, FilmArray and MALDI-TOF MS were investigated. The present studies 
showed that the identification of microorganisms from a single blood culture bottle by 
FilmArray and MALDI-TOF MS were ready in 65 min and 30 minutes respectively. The 
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results from PNA-FISH (AdvanDx, Woburn, MA, USA) and Verigene (Nanosphere, 
Northbrook, IL, USA) are ready in 2-3 h whereas the TAT for Prove-it (Mobidiag, Esbo, 
Finland) is around 5 h.  
The concept of blood culture based rapid identification of microorganisms relies on blood 
culture positivity. However, the high analytical performance of the current rapid methods 
stimulated us to ask the question if we can identify microorganisms from bottles before the 
blood cultures signals positive i.e. semi-culture based identification. In study 2, we analyzed 
the semi-culture based identification by FilmArray.  
In simulated samples, the median TTD of growth for the bottles in the blood culture system 
was 11.1 h, whereas FilmArray could identify microorganisms after 5 h incubation in the 
system. Similar results were obtained when the simulated bottles were incubated for 2.5 h at 
RT before incubation in the blood culture system. When clinical blood culture bottles were 
tested, FilmArray could identify the microorganisms from bottles before culture positivity as 
in the case of simulated samples.   
The TAT of FilmArray with semi-culture based approach can even be compared to TAT of 
non-culture-based molecular diagnostic methods that are performed directly on blood 
samples. The commercial molecular assays including LightCycler SeptiFast test, the 
Magicplex real-time PCR test, the VYOO test, and IRIDICA are currently used as non-
culture based methods. The TAT of these assays is between 6 to 8 h.  
The total time to identification using the semi-culture based approach with the FilmArray is 
around 6 h. The present data indicate that the semi-culture based identification from bottles 
after 5 h of incubation in the blood culture system might be a useful approach in a selected 
number of patients where there is an urgent need for microbiological diagnosis of sepsis. The 
capacity of the methods is another important parameter in TAT of the rapid identification of 
microorganisms.  
Each FilmArray instrument can analyze one sample at a time in 60 min. This is an important 
limitation with the assay. Therefore, the manufacturer has recently presented the next 
generation system with high throughput. The system will be able to analyze up to 12 samples 
simultaneously. In contrast, MALDI-TOF MS can analyze up to 48 samples simultaneously. 
Moreover, the method takes less than 10 minutes to analyze the sample.  
The microorganism coverage is crucial for the performance of rapid identification methods. 
There are several methods that can identify only one microorganism including Xpert 
MRSA/SA Blood Culture (Cepheid, Sunnyvale, CA) or a small number of microorganisms 
such as PNA FISH (AdvanDx, Inc., Woburn, MA). The limited coverage is a significant 
challenge to implement these methods since the method requires information from other tests 
including Gram-staining. Neither FilmArray nor MALDI-TOF MS require prior Gram-
staining in clinical practice.  
  
37 
 
In the first study we showed that the coverage rate of the FilmArray BCID panel is more than 
90% in the studied material. Interestingly, six of thirteen of the microorganisms not included 
in the BCID panel were Micrococcus species, Bacillus species and Corynebacterium species 
that were detected in only one of the bottles of the blood culture sets indicating that the 
microorganisms were probably contaminants from the skin flora.  
Therefore it is plausible to suggest that the FilmArray BCID panel covers the majority of the 
clinically relevant microorganisms. Regarding MALDI-TOF MS, the method has one of the 
largest microorganism coverage among the identification methods in clinical microbiology.  
The MALDI-TOF MS that was used in study 2, 3 and 4 has more than 5000 microorganisms 
in its database. PNA-FISH (AdvanDx, Woburn, MA, USA) includes only 2 to 3 different 
microorganisms in each test kit. Verigene (Nanosphere, Northbrook, IL, USA) includes two 
different test kits which are chosen according to Gram-staining result. The Gram-positive kit 
covers 11 microorganisms and three resistance markers whereas the Gram-negative kit 
includes 8 microorganisms and 5 resistance markers.  
Finally Prove-it (Mobidiag, Esbo, Finland) has the broadest coverage among the panel based 
molecular methods with more than 60 microorganisms and 3 resistance markers in the panel.   
One of the most striking examples of the significance of microorganism coverage was 
observed in study 3. Two anaerobic bacteria that were previously identified from subcultures 
by the conventional method Vitek2 XL (bioMérieux, France) as B. fragilis and Prevotella 
species identified by MALDI-TOF MS from bottles as A. finegoldii and P. goldsteinii 
respectively.  
The MALDI-TOF MS results were confirmed later by sequencing. The analytical 
performance is crucial in implementation of rapid microbiological methods in the clinical 
routine. It is important to note that the characteristics of the clinical samples play a major role 
in the measuring the performance of the methods. Karolinska University Laboratory receives 
blood culture samples from a wide range of clinical wards including several ICUs in 
Stockholm area.  
Therefore we believe that the clinical samples used in evaluation of the methods represent a 
sufficient diversity in terms of microorganisms and patients in order to draw conclusions for 
the performance of the methods analyzed in our studies.  
The most common form of sepsis is caused by a single microorganism. In the first study we 
analyzed the performance of a multiplex PCR method, FilmArray, in identification of 
microorganisms in a prospective clinical material (Altun et al., 2013).  
We showed that FilmArray could identify all microorganisms in 91.6% of the blood culture 
bottles with monomicrobial growth. Several previous studies have described the performance 
of other rapid identification methods including PNA-FISH (AdvanDx, Woburn, MA, USA), 
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Verigene (Nanosphere, Northbrook, IL, USA) and Prove-it (Mobidiag, Esbo, Finland) and 
MALDI-TOF MS (Brucker Daltonics, Bremen, Germany). The analytical performances of 
these methods were high and comparable to our findings with sensitivity rates between 76-
100 % (Hartmann et al., 2005, Bhatti et al., 2014, Liesenfeld et al., 2014, Patel, 2013). 
It is increasingly common to isolate microorganisms that are fastidious, slow growing and 
difficult to culture. One of the most common types of such microorganisms is anaerobic 
bacteria. The subculture process for anaerobic bacteria is extremely long and is up to several 
days. Therefore, identification of anaerobic bacteria directly from blood culture bottles is very 
clinically relevant.  
The broad spectrum of anaerobic microorganism present in MALDI-TOF MS database 
inspired us to test the method for identification of anaerobic bacteria.  Previous studies 
analyzing the performance of MALDI-TOF MS in identification of microorganisms from 
bottles included very limited numbers of bottles with anaerobic bacteria and therefore showed 
promising results but were inconclusive (Leli et al., 2013, Moussaoui et al., 2010). 
In study 3, we analyzed the performance of MALDI-TOF MS in identification of anaerobic 
bacteria from four different blood culture bottle types. MALDI-TOF MS could identify 
anaerobic bacteria in between 75-79% of the different blood culture bottle types. The study 
with more than 65 anaerobic bacteria showed that the MALDI-TOF MS can be used in 
identification of anaerobic bacteria from bottles in the clinical routine (Almuhayawi et al., 
2015). 
As in the case of rare isolates, the incidence of detection of polymicrobial growth in blood 
culture bottles is increasing. This is an obvious challenge both for conventional and rapid 
identification methods (Lin et al., 2010, Dodemont et al., 2014).  
In study 1 and 4 we evaluated the performance of rapid methods in identification of 
polymicrobial growth directly from blood culture bottles after positivity.  FilmArray correctly 
identified all microorganisms in 17/24 (71%) and 99/115 (86.1%) of the BC bottles in study 1 
and 4 respectively.  
It is important to note that 4/24 (17%) and 16/115 (14%) of the bottles with polymicrobial 
growth included three different microorganisms. The results showed that FilmArray is a 
reliable method for rapid identification of polymicrobial samples from positive blood culture 
bottles.  
In contrast to promising FilmArray results, the present MALDI-TOF MS method showed 
poor performance in identification of microorganisms from blood culture bottles with 
polymicrobial growth. The method could identify both microorganisms in only 2/115 (1.7%) 
blood culture bottles.  
The present results obtained by MALDI-TOF MS are in line with the previously published 
studies (Kok et al., 2011, Martinez et al., 2014). The difference between the performance of 
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FilmArray and MALDI-TOF MS in identification of microorganisms from bottles with 
polymicrobial growth is probably due to the target molecules in the two methods. FilmArray 
can detect genes and discriminate microorganisms.  
In contrast MALDI-TOF MS compare an unknown isolate's protein profile to those of a 
reference database, more than one protein profile in the sample result in difficulties in 
identification of different microorganisms.  
An additional advantage with the current rapid methods is the possibility to detect a number 
of resistance markers. FilmArray includes three antibiotic resistance markers: mecA, 
vanA/vanB, and the KPC. Among the positive blood culture bottles in study 1 and 4, there 
were only 3 MRSA in 306 (0.98%) blood cultures. FilmArray could correctly detect mecA 
gene in all three samples.  
The complex work flow and limited resources in today’s clinical microbiological diagnosis of 
sepsis require that the rapid methods to be user friendly. The FilmArray is easy to perform 
and requires less than 5 minutes hands-on time. Blood culture broth from the bottle is directly 
applied without a preparation step. In contrast, the MALDI-TOF MS method requires 
preferable pure cultures of microorganisms.  
The blood cells, cell debris and proteins present in the culture media interact with MALDI-
TOF MS analysis and may affect spectral peak analysis from organisms cultured in these 
matrices (Ferroni et al., 2010). Therefore the blood culture broth should be prepared and the 
microorganisms need to be purified prior to MALDI-TOF MS analysis. This is a time 
consuming process and takes between 20-30 min per sample with 10-15 min hands on time.  
The goal with the development of rapid identification methods is to implement these methods 
in the clinical routine.  
The data from present studies indicate that FilmArray is a reliable method that can be 
implemented in the clinical routine. In addition the data from study 3 showed that MALDI-
TOF MS can be used for microorganisms including anaerobic bacteria that are not present in 
FilmArray BCID panel.  
However, there are several other factors that play important role in choosing the optimal rapid 
identification method including the size of the laboratory, numbers of positive blood cultures 
per day, laboratory staffing, patient and provider types and local resistance rates. These 
factors should be taken into consideration when implementing rapid identification methods in 
clinical practice. 
The present studies have several limitations including lack of clinical data. It is therefore not 
possible to draw conclusions on possible contaminants detected in clinical samples during the 
study. However, we analyzed the data from other blood culture samples registered in the 
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laboratory information system in order to estimate the blood cultures with contaminants as 
described in study 1.  
Similarly, the information from the rapid identification methods obtained during the studies 
was not used in the clinical routine. Therefore it is not possible to measure the clinical impact 
of the present methods in our studies. However, the clinical impact of rapid blood culture 
diagnostics on clinical and economic outcomes has been difficult to analyze. There are 
several studies with contradictory results (Sango et al., 2013, Forrest et al., 2006, Holtzman et 
al., 2011). 
The underlying reason for different results might depend on multiple factors, including the 
level of antimicrobial resistance, patient profile, treatment policies and the clinical staff 
implementing the information from microbiology laboratory in patient treatment. Another 
limitation would be the use of simulated blood culture bottles in study 2, 3 and 4.  
The clinical samples might include parameters that differ from the simulated cultures. These 
may include variable composition of blood cells, antimicrobial agents and transport time of 
blood culture bottles that are normally observed in clinical blood cultures.  
However, appropriate studies in detection of rare microorganisms such as anaerobic bacteria 
and rare clinical conditions such as polymicrobial sepsis in prospective clinical studies would 
be tremendously difficult. The information obtained from simulated samples might probably 
reflect the analytical performance of the methods in the clinical routine. 
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6 CONCLUSION 
The present thesis shows that the FilmArray is a reliable method for identification of 
microorganisms from positive blood culture bottles with mono- as well as polymicrobial 
growth. The data from the studies showed also that it is possible to improve the use of rapid 
identification methods as in the case of semi-culture based identification.  
This approach describes the identification of microorganisms from blood culture bottles using 
FilmArray before the bottles signal positive in the system.  
This unique approach may be used in a selective group of patients as a reliable alternative 
candidate to non-culture based methods. In addition we showed that rapid identification 
methods with broad coverage such as MALDI-TOF MS can be used in identification of rare 
microorganisms including anaerobic bacteria. 
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